Proactive Investors - Run By Investors For Investors

Epistem clinical trial go-ahead marks important milestone - Chairman

Ian Gilham, chairman of Epistem Holdings (LON:EHP) says clinical trials of its genedrive diagnostic test for Hepatitis C (HCV) will start immediately and “probably run until the third of fourth quarter of this year.”

Once the studies are finalised and results collated the company will begin the registration process towards a CE marked product which Gilham anticipates will be “sometime in 2017.”

The qualitative HCV test was developed in collaboration with Inserm, the French National Institute of Health and Medical Research, under a €6m EU supported programme and cleared for clinical trials by the Institut Pasteur in Paris.

Meet Anglo Asian Mining Plc, Landore Resources Ltd., Stratex International plc and Chaarat Gold Holdings Ltd at our event, London, 03 November 2016. Register here »

Register here to be notified of future Genedrive PLC articles
View full GDR profile

Genedrive PLC Timeline

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.